We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for mogamulizumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
mogamulizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for IV administration
Indication
For the treatment of cutaneous t-cell lymphoma
Therapeutic area
Haematology